NEWS
PRESS RELEASES
ARTICLES
CALENDAR
06.12.13 – 06.14.13
CALBIO Summit 2013 (Bassil Dahiyat, Ph.D., presenting; San Diego, CA)
SiteMap
Feeds
Authors
Pages
- Careers
- Contact
- Location
- SiteMap
- PROTEINS BY DESIGN
- COMPANY
- PRODUCTS
- TECHNOLOGY
- PARTNERING
- INVESTOR RESOURCES
- NEWS
Categories
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- September 2012
- August 2012
- July 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- March 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- June 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- August 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- June 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- July 2007
- June 2007
- February 2007
- January 2007
- October 2006
- September 2006
- July 2006
- March 2006
- February 2006
- January 2006
- December 2005
- October 2005
- July 2005
- June 2005
- April 2005
- January 2005
- December 2004
- February 2004
- January 2004
- December 2003
- September 2003
- January 2003
- October 2002
- June 2002
- May 2002
- April 2002
- March 2002
- February 2002
- January 2002
- October 2001
- August 2001
- July 2001
- June 2001
- June 1999
- January 1999
- November 1998
- January 1998
- January 1997
- January 1996
Posts
ARTICLES
- FierceBiotech: Xencor spotlighted as one of 10 Next-Gen Biologics Platforms
- Stranger in a strange land? - Xencor’s CEO provides advice for fledgling entrepreneurs in academia.
- BioWorld Today Peeks Behind the BIO Partnering Curtain - BIO 2012
- Innovation Over Imitation: Pharmaceutical Executive
- Research Shows Proteins Could Be Customized For Better Clinical Results: BioWorld Today
- Making Proteins - Interview Bassil Dahiyat and Stephen Mayo: NPR Science Friday
- No Assembly Required: Engineering and Science, Caltech, Vol 4.
- Caltech Prof Offers Insight Into Start-Up Success: Los Angeles Times
- Protein Redesigned for Greater Stability: Chemical & Engineering News
- Better Than Mother Nature: Forbes
- Xencor Raises $12M For Computational Design Work: BioWorld Today
- Money's There, but hurdles Abound: Los Angeles Times
- Encouraging Entrepreneurship: Chemical & Engineering News
- A Kinder cure. How to spot drugs that misfire: New Scientist Magazine
- Designer Enzymes: The Economist
- CEO Interview, September 2001: The Wall Street Transcript
- Proteins In 3-D: Signals Magazine
- Preventive Medicine: By hook or crook, Xencor looks to take the mystery out of drug discovery: The Zone News
- Designer Cosmetics: Biotech in Personal Care: Chemical & Engineering News
- Xencor Gets Real: BioCentury Technology Briefing
- Xencor Researchers Focus on TNF-Blocking Drugs: BioWorld Today
- The Protein Engineers: BioCentury
- Fc Regions: Next Advance in Antibody Drug Research: BioWorld Today
- The Protein Engineers: BioCentury
- Xencor To Use PDA Technology To Optimize Protein In Lilly Deal: BioWorld Today
- Fc Regions: Next Advance in Antibody Drug Research: BioWorld Today
- Xencor Gets Real: BioCentury
- More Freedom To Deal: BioCentury
- Xencor to Spruce Up Pfizer Antibodies: The Pink Sheet
- Building Better Proteins: The Scientist
- Signs of ma(b)turity: BioCentury
EVENTS
- 06.12.13 - 06.14.13
- 04.29.13 - 05.03.13
- 02.26.13 - 02.27.13
- 11.09.12 - 11.14.12
- 01.24.13 - 01.25.13
- 11.26.12 - 11.30.12
- 09.24.12 - 09.26.12
- 09.10.2012 - 09.12.2012
- 05.20.12 - 05.23.12
- 03.26.12 – 03.28.12
- 03.25.12 - 03.30.12
- 03.19.12 – 03.22.12
- 02.29.12 – 03.02.12
- 02.29.12 - 03.02.12
- 01.30.12 - 01.31.12
- 01.30.12 - 01.31.12
- 01.11.12 - 01.12.12
- 12.04.11 - 12.08.11
- 11.04.11 – 11.09.11
- 10.11.11 - 10.13.11
- 08.01.11 - 08.03.11
- 06.27.11 - 06.30.11
- 09.03.11 - 09.06.11
- 05.13.11 - 05.18.11
- 05.09.11 – 05.13.11
- 03.18.11 – 03.22.11
- 03.16.11 – 03.18.11
- 12.05.10 – 12.09.10
- 11.06.10 – 11.11.10
- 10.18.10 – 10.19.10
- 10.05.10 – 10.06.10
- 09.26.10 – 09.29.10
- 09.22.10 – 09.23.10
- 06.08.10 – 06.09.10
- 06.09.10 – 06.10.10
- 02.26.10 – 03.02.10
- 01.08.10 – 01.13.10
- 12.08.09 – 12.10.09
- 11.12.09 – 11.13.09
- 10.18.09 – 10.21.09
- 10.11.09 – 10.14.09
- 08.03.09 – 08.05.09
- 06.22.09 – 06.24.09
- 05.29.09 – 06.02.09
- 04.26.09 – 04.29.09
- 04.18.09 – 04.22.09
- 04.06.09 – 04.10.09
- 03.27.09 – 04.01.09
- 01.12.09 – 01.14.09
- 12.09.08 – 12.11.08
- 12.07.08 – 12.11.08
- 11.20.08 – 11.21.08
- 10.31.08 – 11.02.08
- 10.26.08 – 10.29.08
- 10.22.08 – 10.23.08
- 10.06.08 – 10.08.08
- 09.7.08 – 09.09.08
- 06.24.08 – 06.26.08
- 06.17.08 – 06.20.08
- 04.12.08 – 04.16.08
- 03.27.08 – 03.27.08
- 03.07.08 – 03.08.08
- 02.13.08 – 02.17.08
- 02.11.08 – 02.13.08
- 01.07.08 – 01.09.08
- 12.12.07 – 12.13.07
- 12.12.07 – 12.13.07
- 12.08.07 – 12.11.07
- 12.02.07 – 12.06.07
- 11.04.07 – 11.07.07
- 10.04.07 – 10.05.07
- 09.25.07 – 09.27.07
- 07.16.07 – 07.17.07
- 06.26.07 – 06.28.07
- 06.17.07 – 06.20.07
EVENTS TEST
PRESENTATIONS
- Atlanta, GA; December 10-13, 2005
- IBC Protein Engineering for Biotherapeutics Conference
- IBC Protein Engineering for Biotherapeutics Conference; San Diego, December 12-14, 2006 (Fc)
- American College of Rheumatology (ACR): Innovative Therapies in Autoimmune Diseases; Arlington, VA, March 2-4, 2007
- American Association for Cancer Research (AACR) Annual Meeting; Los Angeles, April 14-18, 2007 (CD19)
- American Association for Cancer Research (AACR) Annual Meeting; Los Angeles, April 14-18, 2007 (Fc)
- Life Sciences 2007; Glasgow, UK, July 8-12, 2007 (Fc)
- 7th International Symposium on Hodgkin Lymphoma; Cologne, Germany, November 3-7, 2007 (CD30)
- IBC Life Sciences' 17th Annual Antibody Engineering Conference; San Diego, December 2-6, 2007 (CD19)
- American Society of Hematology 49th Annual Meeting and Exposition; Atlanta, GA, December 8-11, 2007 (CD30)
- American Association for Cancer Research (AACR) Annual Meeting; San Diego, April 12-16, 2008 (CD19)
- XmAb®5574: an Fc-Engineered Anti-CD19 Monoclonal Antibody with In Vitro and In Vivo Efficacy against Lymphoma and Leukemia
- Phase 1 study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients;
PRESS RELEASES
- Monoclonal Antibody with Xencor’s High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
- Xencor Licenses Xtend™ Therapeutic Protein Half-life Extension Technology to CSL
- Xencor Initiates Phase 1b/2a Trial of XmAbR5871 for Autoimmune Disease
- Xencor Receives Milestone Payment for Xtend™ Antibody
- MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574 - Phase 1/2a Trial in CLL/SLL Patients Met Primary and Secondary Objectives
- MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL - Study Data Expected in Q4 2012
- Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration
- Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
- Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
- Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response
- Xencor's Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology
- Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases
- Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
- Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
- MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
- Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
- Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience
- Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement
- Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
- Xencor Licenses Antibody Optimization Technology
- Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board
- Xencor Presents Preliminary Phase 1 Data on XmAb®2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting
- Xencor to Present Phase 1 Data on XmAb®2513 Antibody for Lymphomas at the American Society of Clinical Oncology Annual Meeting
- Xencor Licenses Xtend™ Antibody Half-life Prolongation Platform to Merck & Co., Inc.
- Xencor and Pfizer enter into Antibody Technology Licensing Agreement
- Xencor and CSL Limited Establish Antibody Optimization Collaboration
- Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology
- Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference
- Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO
- Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR
- Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings
- Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors
- Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma
- Human Genome Sciences And Xencor Announce Antibody Collaboration
- Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology
- Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting
- Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease
- Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
- Xencor Expands Series E Financing to $60 Million
- Xencor Selects Antibody Development Candidates
- Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease
- Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
- Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures
- Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award
- Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors
- Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells
- Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc.
- Lilly Licenses Xencor's Immunofilter™ Technology
- Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
- MedImmune Licenses Xencor's XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year
- Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing
- Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies
- FierceBiotech Honors Xencor as One of the
- Xencor Licenses Protein Variants to Lilly
- Xencor and Chugai Initiate Partnership for Optimized Antibodies
- Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics
- Xencor Announces Protein Optimization Collaboration with Lilly
- Xencor Determines Structure Of Baff, A Key Autoimmune Disease Target
- Xencor and Protein Design Labs Initiate Partnership for Optimized Antibodies
- Xencor Announces Bassil Dahiyat As Its New Chief Scientific Officer
- Xencor Announces Harry Stylli As Its New Chief Executive Officer
- Xencor Designs Novel TNF Alpha Inhibitors To Treat Inflammatory Disease
- Xencor Granted Patent on Optimized Pharmaceutical Protein
- Chromos and Xencor announce agreement for use of the ACE System to produce biologics.
- Bassil Dahiyat Named One of the World's Top Young Innovators
- Xencor Receives Advanced Technology Program Grant For Safer Protein Therapeutics
- Xencor Reaches Research Milestone
- Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier
- Xencor Optimizes Key Pharmaceutical Proteins
- Chemical Genomics - CALBIOsummit 2002 April 21,22,23
- Xencor Licenses Patent For Chemical Genomics Technology Profiling Biological And Pharmacological Interactions
- Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products
- Syngenta's Torrey Mesa Research Institute And Xencor Sign Research And License Agreement
- Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs
- Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products
- Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts
- Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins
- Xencor Closes $12.3 Million in Financing
- Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting
- Xencor Licenses Caltech Technology
PUBLICATIONS
- Matthew J. Bernett, Seung Y. Chu, Irene Leung, Gregory L. Moore, Sung-Hyung Lee, Erik Pong, Hsing Chen, Sheryl Phung, Umesh S. Muchhal, Holly M. Horton, Greg A. Lazar, John R. Desjarlais, David E. Szymkowski (2013)
- Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US (2012)
- Chu SY, Horton H, Pong E, Leung I, Chen H, Nguyen D-H, Bautista C, Muchhal US, Bernett M, Moore GL, Szymkowski DE, Desjarlais JR (2012)
- Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE (2012)
- Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA (2011)
- JR Desjarlais and GA Lazar (2011)
- Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE (2011)
- Maillet I, Schnyder-Candrian S, Couillin I, Quesniaux VF, Erard F, Moser R, Fleury S, Kanda A, Dombrowicz D, Szymkowski DE, Ryffel B (2011)
- Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, and Eugene A. Zhukovsky (2010)
- Moore GL, Chen H, Karki S, and Lazar GA (2010)
- Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, and Byrd JC (2010).
- Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010).
- Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, and Lazar GA (2010)
- Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE (2009)
- Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Vostiar, Patrick F. Joyce, Roland Repp, John R. Desjarlais, and Eugene A. Zhukovsky (2008)
- Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR (2008)
- John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang, and John R. Desjarlais (2008)
- Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007)
- Zhu M.M., Mollet M., and Hubert R.S. (2007)
- Jonathan Zalevsky, Thomas Secher, Sergei A. Ezhevsky, Laure Janot, Paul M. Steed, Christopher O'Brien, Araz Eivazi, James Kung, Duc-Hanh T. Nguyen, Stephen K. Doberstein, Francois Erard, Bernhard Ryffel, and David E. Szymkowski (2007)
- Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., and Hammond P.W. (2007)
- Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat, B.I. (2006)
- Barbosa, M.D.F.S., Vielmetter, J., Seung, C., Smith, D.D., and Jacinto, J. (2006)
- Szymkowski D.E. (2005)
- Vielmetter J. et al. (2005)
- Szymkowski D.E. (2005)
- Szymkowski D.E. (2004)
- Zhukovsky E.A. and Morse R.J. (2004)
- Chirino A. J. and Mire-Sluis A. (2004)
- Zhukovsky E.A., Lee J.O., Villegas M., Chan C., Chu S., Mroske C. (2004)
- Chirino, A.J., Ary, M.L., Marshall, S.A. (2004)
- Steed, P.M. et al. (2003)
- Lazar, G.A., Marshall, S.A., Plecs, J.J., Mayo, S.L., Desjarlais, J.R. (2003)
- Szymkowski D.E. (2003)
- Marshall, S.A., Lazar, G.A., Chirino, A.J., Desjarlais, J.R., (2003)
- Filikov, A.V., Hayes, R.J., Luo, P., Stark, D.M., Chan, C., Kundu, A., and Dahiyat, B.I. (2002)
- Hayes, R.J., Bentzien, J., Ary, M.L., Hwang, M.Y., Jacinto, J.M., Vielmetter, J., Kundu, A., and Dahiyat, B.I. (2002)
- Luo, P, Hayes, R.J., Chan, C., Stark, D.M., Hwang, M.Y., Jacinto, J. M., Juvvadi, P., Chung, H.S., Kundu, A., Ary, M.L., and Dahiyat, B.I. (2002)
- Dahiyat, B. I., (1999)
- Malakauskas, S. M., and Mayo, S. L., (1998)
- Dahiyat, B., Gordon, D., and Mayo, S. L. (1997)
- Dahiyat, B. I., and Mayo, S. L., (1997)
- Dahiyat, B. I., and Mayo, S. L., (1997)
- Dahiyat, B. I., and Mayo, S. L., (1996)
